Pyxis Oncology announced a financing through a private placement of 19,600,153 common shares at $2.551 per share with accompanying common warrants, expected to yield approximately $50.0 million in gross proceeds at closing. The warrants, exercisable at $3.289 after MICVO Phase 1 data disclosure or by Oct 1, 2026, could add roughly $64.0 million if fully exercised for cash and expire on Jul 2, 2029. The company also signed a Registration Rights Agreement to register the resale of the shares and warrant shares, with a filing deadline of Oct 2, 2026. Proceeds are expected to extend the cash runway into Q2 2027 and fund MICVO clinical milestones.
Agreement 1: Pyxis Oncology Raises $50 Million in Private Placement; Warrants Could Add ~$64 Million
- Agreement type: Securities Purchase Agreement for private placement of common stock and warrants
- Counterparty: Institutional and accredited investors
- Signed / Effective: Jun 30 2026 / Jul 02 2026
- Reason: Strengthen cash runway and fund MICVO clinical milestones
Agreement 2: Pyxis Oncology Grants Registration Rights for Private Placement Shares and Warrant Shares
- Agreement type: Registration Rights Agreement for resale of private placement securities
- Counterparty: Institutional and accredited investors
- Signed / Effective: Jul 02 2026 / Jul 02 2026
- Duration / Termination: Until all registrable securities are sold or freely tradeable
- Reason: Provide liquidity pathway for private placement investors
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.